Europe

Views & Analysis

Patients as Partners Europe: Are we doing patient centricity...

To be truly patient centric, do we need to turn the current model on its head and work within a more free-thinking, free-speaking framework?

Market Access

Why cell therapy manufacture is a team sport

Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that sits behind the process of individualised cell therapy – and why team cult

Views & Analysis

The calm after the storm: How COVID-19 is making pharma more...

COVID-19 is proving to be the perfect storm in terms of the supply of pharmaceutical products.

Views & Analysis

Germany’s digital health changes will boost digital therapeu...

Digital therapeutics are gaining momentum worldwide and offer developers, including pharma, both a huge opportunity and a stimulating market access challenge, say Olaf Schoeman and Emanuele

News

EMA starts rapid review of Bluebird’s gene therapy for rare ...

Bluebird bio could be just a few months away from approval of its gene therapy for rare disease cerebral adrenoleukodystrophy (CALD) in the EU, after the EMA started an accelerated review.<

Views & Analysis